Oncotarget

Addendum:

Addendum: Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment

PDF  |  How to cite

Oncotarget. 2023; 14:149-149. https://doi.org/10.18632/oncotarget.28363

Metrics: PDF 701 views  |   ?  

Gennady M. Zharinov1, Oleg A. Bogomolov1, Irina V. Chepurnaya1, Natalia Yu. Neklasova1 and Vladimir N. Anisimov2

1A.M. Granov Russian Research Center for Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, Pesochny, St. Petersburg 197758, Russia
2N.N. Petrov National Medical Research Center of Oncology, Pesochny, St. Petersburg 197758, Russia

Published: February 25, 2023

Copyright: © 2023 Zharinov et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Patient consent was required and obtained. This study was approved by the Russian Research Centre of Radiology and Surgical Technologies Ethics Committee (Approval #1041Y).

Original article: Oncotarget. 2020; 11:3723–3729. DOI: https://doi.org/10.18632/oncotarget.27757


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28363